- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
MapLight Therapeutics Announces Commencement of Initial Public Offering SAN FRANCISCO AND BOSTON, OCTOBER 6, 2025 – MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange […]
MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel M₁/M₄ agonist, as a potential treatment for Alzheimer’s disease psychosis (ADP).
MapLight Therapeutics today announced an oversubscribed $372.5 million Series D financing.
MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel M₁/M₄ agonist, as a potential treatment for schizophrenia.
MapLight Therapeutics today announced results from its Phase 1 trial evaluating the safety, tolerability and pharmacokinetics of ML-007/PAC in healthy adult and elderly volunteers.
MapLight Therapeutics Appoints Maria Walker to Board of Directors Walker brings 30+ years of investment, operational, and advisory experience SAN FRANCISCO AND BOSTON, APRIL 3, 2024 – MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced […]
MapLight Therapeutics Announces Initiation of Phase 1 Clinical Trial for ML-007/PAC, Under Development for Schizophrenia and Alzheimer’s Disease Psychosis Study to evaluate safety and tolerability of extended-release fixed dose combination ML-007/PAC with precision-matched release kinetics in advance of planned Phase 2 clinical trial ML-007/PAC dosing regimens to be assessed in healthy non-elderly and elderly adults […]
MapLight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer Mr. Setia brings significant advisory and execution experience across capital markets and strategic transactions Jon Gillis will transition to Chief Administrative and Accounting Officer Changes to the executive leadership team support MapLight’s next stage of growth and development SAN FRANCISCO […]
MapLight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M1/M4 Muscarinic Agonist in Development for Schizophrenia and Alzheimer’s Disease Psychosis Extended-release ML-007 was evaluated for safety, tolerability, and pharmacokinetic profile in healthy volunteers across several dosing regimens, alone and when co-administered with an extended-release muscarinic antagonist Extended-release ML-007 was well tolerated at all […]
MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics Funding will support development of multiple clinical candidates to treat neurological and psychiatric disorders, including Phase 2 studies for ML-007C-MA in 2024 in schizophrenia and Alzheimer’s disease psychosis Novo Holdings led a group of top-tier, new investors including […]